title: Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back.
abstract: Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice.
authors.affiliation: Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Avda, Fernando de Casa Novoa, Santiago de Compostela 15707, Spain. Luis.Leon.Mateos@sergas.es.
authors.forename: Luis
authors.initials: L
authors.lastname: León-Mateos
authors.affiliation: London Regional Cancer Program, London Health Sciences Centre, London, ON N6A 4L6, Canada. mariavieito@gmail.com.
authors.forename: María
authors.initials: M
authors.lastname: Vieito
authors.affiliation: Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. urbanoanido@gmail.com.
authors.forename: Urbano
authors.initials: U
authors.lastname: Anido
authors.affiliation: Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. rafa.lopez.lopez@gmail.com.
authors.forename: Rafael
authors.initials: R
authors.lastname: López López
authors.affiliation: Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. lmuirom@gmail.com.
authors.forename: Laura
authors.initials: L
authors.lastname: Muinelo Romay
keywords: circulating tumour cells; precision oncology; prostate cancer; tumour markers